| Mr Robert Liguori, | |
|
15 Sewall St, Portland, ME 04102-2641 | |
| (207) 347-2205 | |
| (207) 347-2206 |
| Full Name | Mr Robert Liguori |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 14 Years |
| Location | 15 Sewall St, Portland, Maine |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013249473 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | CR2002 (Maine) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kate Lynch Dc Llc | 5890059265 | 4 |
News Archive
A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.
USA Today: "The cost of cancer treatment is 'skyrocketing' — both for individual patients and the nation, a new analysis shows. From 1990 to 2008, spending on cancer care soared to more than $90 billion from $27 billion. The increase was driven by the rising costs of sophisticated new drugs, robotic surgeries and radiation techniques, as well as the growing number of patients who are eligible to take them, says Peter Bach of New York's Memorial Sloan-Kettering Cancer Cancer, co-author of an analysis in today's Journal of the American Medical Association.
Heidelberg University Hospital in Germany has entered into a partnership with RaySearch Laboratories AB to pioneer the RayCare™ oncology information system. The research partnership, which focuses on supporting comprehensive cancer care, will involve the hospital and the affiliated sites Heidelberg Ion Beam Therapy Center and Marburg Ion Beam Therapy Center (MIT).
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
The University of Texas System launched a cutting-edge web portal today that allows private sector and government agencies to quickly find thousands of renowned researchers and facilities at the System's campuses and health institutions.
› Verified 5 days ago
| Provider Name | Kate Lynch Dc Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1215359385 PECOS PAC ID: 5890059265 Enrollment ID: O20180511000213 |
News Archive
A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.
USA Today: "The cost of cancer treatment is 'skyrocketing' — both for individual patients and the nation, a new analysis shows. From 1990 to 2008, spending on cancer care soared to more than $90 billion from $27 billion. The increase was driven by the rising costs of sophisticated new drugs, robotic surgeries and radiation techniques, as well as the growing number of patients who are eligible to take them, says Peter Bach of New York's Memorial Sloan-Kettering Cancer Cancer, co-author of an analysis in today's Journal of the American Medical Association.
Heidelberg University Hospital in Germany has entered into a partnership with RaySearch Laboratories AB to pioneer the RayCare™ oncology information system. The research partnership, which focuses on supporting comprehensive cancer care, will involve the hospital and the affiliated sites Heidelberg Ion Beam Therapy Center and Marburg Ion Beam Therapy Center (MIT).
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
The University of Texas System launched a cutting-edge web portal today that allows private sector and government agencies to quickly find thousands of renowned researchers and facilities at the System's campuses and health institutions.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Robert Liguori, 15 Sewall St, Portland, ME 04102-2641 Ph: (207) 347-2205 | Mr Robert Liguori, 15 Sewall St, Portland, ME 04102-2641 Ph: (207) 347-2205 |
News Archive
A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.
USA Today: "The cost of cancer treatment is 'skyrocketing' — both for individual patients and the nation, a new analysis shows. From 1990 to 2008, spending on cancer care soared to more than $90 billion from $27 billion. The increase was driven by the rising costs of sophisticated new drugs, robotic surgeries and radiation techniques, as well as the growing number of patients who are eligible to take them, says Peter Bach of New York's Memorial Sloan-Kettering Cancer Cancer, co-author of an analysis in today's Journal of the American Medical Association.
Heidelberg University Hospital in Germany has entered into a partnership with RaySearch Laboratories AB to pioneer the RayCare™ oncology information system. The research partnership, which focuses on supporting comprehensive cancer care, will involve the hospital and the affiliated sites Heidelberg Ion Beam Therapy Center and Marburg Ion Beam Therapy Center (MIT).
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
The University of Texas System launched a cutting-edge web portal today that allows private sector and government agencies to quickly find thousands of renowned researchers and facilities at the System's campuses and health institutions.
› Verified 5 days ago
Dr. Amy Mooney Lewellen, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 50 Cove St, Suite A, Portland, ME 04101 Phone: 207-828-8777 Fax: 207-828-8778 | |
Wendy Pollock, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 83 India St, Portland, ME 04101 Phone: 207-370-8330 | |
Dr. Mark C Segerstrom, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2001 Congress St, Portland, ME 04102 Phone: 207-879-5433 Fax: 207-879-5433 | |
Andrea Korda-willerson, Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1385 Congress St, Portland, ME 04102 Phone: 207-874-2225 | |
Spinal Wellness Portland Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 47 Portland St, Portland, ME 04101 Phone: 207-780-0300 Fax: 866-265-5910 | |
Riley Noella Jones, Chiropractor Medicare: Medicare Enrolled Practice Location: 949 Brighton Ave, Portland, ME 04102 Phone: 207-780-1070 |